Manulife (Manufacturers Life Insurance)
VRDN icon

Manulife (Manufacturers Life Insurance)’s Viridian Therapeutics VRDN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59M Sell
81,425
-31,257
-28% -$928K ﹤0.01% 1590
2025
Q4 		$3.5M Buy
112,682
+29,182
+35% +$800K ﹤0.01% 1323
2025
Q3 		$1.8M Buy
83,500
+4,985
+6% +$89.9K ﹤0.01% 1564
2025
Q2 		$1.1M Buy
78,515
+18,280
+30% +$248K ﹤0.01% 1777
2025
Q1 		$812K Buy
60,235
+10,515
+21% +$179K ﹤0.01% 1903
2024
Q4 		$953K Buy
49,720
+24,988
+101% +$543K ﹤0.01% 1932
2024
Q3 		$563K Sell
24,732
-6,955
-22% -$114K ﹤0.01% 2221
2024
Q2 		$412K Buy
31,687
+7,450
+31% +$103K ﹤0.01% 2293
2024
Q1 		$424K Buy
24,237
+8,182
+51% +$159K ﹤0.01% 2263
2023
Q4 		$350K Sell
16,055
-356
-2% -$5.62K ﹤0.01% 2334
2023
Q3 		$252K Sell
16,411
-577
-3% -$11K ﹤0.01% 2456
2023
Q2 		$404K Buy
16,988
+1,951
+13% +$50K ﹤0.01% 2176
2023
Q1 		$383K Buy
15,037
+609
+4% +$19.5K ﹤0.01% 2169
2022
Q4 		$421K Buy
14,428
+3,789
+36% +$87.3K ﹤0.01% 2098
2022
Q3 		$218K Sell
10,639
-89
-0.8% -$1.6K ﹤0.01% 2530
2022
Q2 		$124K Buy
+10,728
New +$144K ﹤0.01% 2837
2018
Q3 		– Sell
-1,475
Closed -$142K – 3859
2018
Q2 		$142K Buy
1,475
+1,058
+254% +$112K ﹤0.01% 3323
2018
Q1 		$44K Buy
417
+194
+87% +$21.1K ﹤0.01% 3574
2017
Q4 		$35K Buy
223
+180
+419% +$22.9K ﹤0.01% 3632
2017
Q3 		$6K Buy
43
+38
+760% +$6.39K ﹤0.01% 4001
2017
Q2 		$1K Buy
+5
New +$844 ﹤0.01% 4271

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s VRDN Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Viridian Therapeutics (VRDN) stake by 28% in Q1 2026, selling an estimated $928K and leaving 81,425 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Manulife (Manufacturers Life Insurance) first reported a position in VRDN in Q2 2017 and has held it in 21 quarters since. The position peaked at $3.5M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 81,425 shares of Viridian Therapeutics worth $1.59M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 31,257 Viridian Therapeutics shares in Q1 2026, an estimated $928K.
  • Viridian Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1590 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Viridian Therapeutics position peaked at $3.5M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.